Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Steroid Reduction Lowers Toxic Effects in Kidney Transplants

By HospiMedica staff writers
Posted on 29 Aug 2006
Preliminary results of a new study suggest that reducing corticosteroid treatment in kidney transplant patients significantly lowers the toxic side effects of anti-rejection drugs without affecting survival rates. More...


Researchers at the University of Cincinnati (UC, OH, USA) followed 397 patients enrolled in a national study conducted at 26 medical centers across the United States, who were then randomized to either a seven-day or lifetime course of corticosteroid therapy, which started within the first three days of transplant. Patients in both treatment groups received the steroids in combination with twice-daily tacrolimus and mycophenolate mofetil, immunosuppressive agents designed to help lower the body's natural immunity to the transplant organ.

The study found that patients who received just seven days of the corticosteroid prednisone after kidney transplant had the same transplant organ survival rate and functionality as those placed on continuous corticosteroids. The study found that biopsy-proven acute rejection rate for steroid-free patients was 16%, only slightly higher than the nationwide average of 15%. Steroid-free patients, however, experienced significantly less cardiovascular risk, including cholesterol levels, blood pressure, and weight gain.

In addition, UC researchers found that African-Americans--long excluded from transplant research trials because of a perceived risk for increased acute rejection--are not at any greater risk for rejection than Caucasians and actually enjoy even greater benefits in terms of cardiovascular risk reduction. The results presented were for the first three years of the projected five-year investigation. The study was reported at the World Transplant Congress, the first international joint-organizational transplant conference, held in July 2006 in Boston (MA, USA).

"When you ask transplant patients about their medicines, they say the drug they dislike most is steroids. They don't want to take steroids because of what the drugs do to their bodies,” said lead author Steve Woodle, M.D., director of transplantation at UC. "They see how the drug's toxicity affects their bodies--their faces swell, they gain weight, they bruise easily--and they know steroids are the cause.”



Related Links:
University of Cincinnati

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammo DR Retrofit Solution
DR Retrofit Mammography
Mammography System (Analog)
MAM VENUS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.